Sökning: id:"swepub:oai:DiVA.org:oru-81041" >
Immune checkpoint i...
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer : promise, controversies and ambiguities in the novel treatment paradigm
-
- Breimer, Lars H. (författare)
- Örebro University,Örebro University Hospital
-
- Nousios, Petros (författare)
- Örebro University,Örebro University Hospital
-
- Olsson, Louise, 1960- (författare)
- Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Centre for Assessment of Medical Technology in Örebro,Örebro University Hospital
-
visa fler...
-
- Brunnström, Hans (författare)
- Lund University,Lunds universitet,Förbättrad diagnostik och prognostik vid lungcancer och metastaser till lunga,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Improved diagnostics and prognostics of lung cancer and metastases to the lungs,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments
-
visa färre...
-
(creator_code:org_t)
- 2020-04-02
- 2020
- Engelska.
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - : Taylor & Francis. - 0036-5513 .- 1502-7686. ; 80:5, s. 360-369
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://www.tandfonl...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests can be discussed. In addition, monitoring for side-effects involves increased workload and budgetary expense for clinical chemistry laboratories. Here, we review and summarize the current knowledge, controversies and ambiguities of ICIs for the treatment of NSCLC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- Non-small-cell lung carcinoma
- PD-1/PD-L1
- biomarkers
- immune checkpoint inhibition
- pharmaceutical economics
- biomarkers
- immune checkpoint inhibition
- Non-small-cell lung carcinoma
- PD-1/PD-L1
- pharmaceutical economics
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas